Features of the metabolic syndrome and prostate cancer in African-American men

Cancer

Volumn 109, Issue 5, 2007, Pages 875-881

  Beebe Dimmer, Jennifer L ^a   Dunn, Rodney L ^b   Sarma, Aruna V ^a,b   Montie, James E ^b   Cooney, Kathleen A ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Abdominal obesity; African Americans; Diabetes; Hypertension; Prostate cancer

Indexed keywords

GLUCOSE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY COMPOSITION; CANCER INCIDENCE; CONTROLLED STUDY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MINORITY GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; SELF REPORT; WAIST CIRCUMFERENCE;

ADULT; AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 33847346957     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22461     Document Type: Article

References (31)

1. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
2. National Institutes of Health. Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication no. 01-3670. Bethesda, Md: National Institutes of Health; 2001.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults-findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
4. Smith SC Jr, Clark LT, Cooper RS, et al. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation. 2005;111:e134-e139.
5. Okosun IS, Chandra KM, Boev A, et al. Abdominal adiposity in U.S. adults: prevalence and trends, 1960-2000. Prev Med. 2004;39:197-206.
6. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Pressure. 2004;13:47-55.
7. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006;164:769-774.
8. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004;13:1646-1650.
9. Nomura AM. Body size and prostate cancer. Epidemiol Rev. 2001;23:126-131.
10. Hsing AW, Gao YT, Chua S, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003;95:67-71.
11. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11:534-542.
12. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
13. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev. 2002;3:303-308.
14. Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ. 2000;321:847-848.
15. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 1991;73:401-407.
16. Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. Horm Metab Res. 1994;26:81-84.
17. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev. 2001;23:59-66.
18. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control. 2005;16:255-262.
19. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2003;12:1410-1416.
20. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108:418-424.
21. Hsing AW, Deng J, Sesterhenn IA, et al. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prevent. 2000;9:1335-1341.
22. Ceriello A. Oxidative stress and glycemic regulation. Metabolism. 2000;49:27-29.
23. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002;5:551-569.
24. Ness KK, Oakes JM, Punyko JA, Baker KS, Gurney JG. Prevalence of the metabolic syndrome in relation to self-reported cancer history. Ann Epidemiol. 2005;15:202-206.
25. Friedman GD. Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol. 1997;7:486-489.
26. Karter AJ, D'Agostino RB Jr, Mayer-Davis EJ, et al. Abdominal obesity predicts declining insulin sensitivity in non-obese normoglycaemics: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Obes Metab. 2005;7:230-8.
27. Dalton M, Cameron AJ, Zimmet PZ, et al. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med. 2003;254:555-563.
28. Sierra-Johnson J, Johnson BD, Allison TG, Bailey KR, Schwartz GL, Tumer ST. Correspondence between the Adult Treatment Panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care. 2006;29:668-672.
29. Rockwood K, Await E, MacKnight C, McDowell I. Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian Study of Health and Aging. CMAJ. 2000;162:769-772.
30. Klabunde CN, Reeve BB, Harlan LC, Davis WW, Potosky AL. Do patients consistently report comorbid conditions over time? Results from the Prostate Cancer Outcomes Study. Med Care. 2005;43:391-400.
31. Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107:2361-2367.